Archive

Oligorecurrent and oligoprogressive NSCLC

Oligorecurrent and oligoprogressive NSCLC represent a treatment challenge. A case example of synchronous oligometastatic disease provided the framework for expert discussion……..    Written by Christine Clark.

Immunotherapy in thoracic malignancies: what has been achieved in 2019?

Advances in the use of immunotherapy in thoracic malignancies continued in 2019 with the publication of the results of a number of landmark trials. This has prompted some… read more.

Expert insights in advanced ALK-positive NSCLC

Three expert clinicians, Dr Marina Garassino, Dr Sanjay Popat and Professor Tony Mok presented and discussed cases that illustrated important aspects of the management of ALK-positive NSCLC …… … read more.

Late breaking abstracts – FLAURA study

The final analyses of two key trials – Checkmate 227, part 1 and FLAURA should help to position nivolumab + ipilimumab combination treatment and to reinforce osimertinib as… read more.

Highlights from ESMO 2019

For the second time this year, LungCancer.Med headed to Barcelona for the Annual European Society for Medical Oncology (ESMO) meeting.  Written by Christine Clark

Highlights from IMW 2019

Many of the 4,000 delegates at IMW in Boston this year, such as Professor Mohamad Mohty (Paris, France) highlighted the spirit of collaboration, with locals Professor Paul Richardson and Professor Noopur Raje discussing their highlights… read more.

IMW 2019: Relapsed/refractory myeloma: ongoing challenges and emerging hope

Article written by Tom Collins. Interview by Esther Drain.

Pomalidomide with bortezomib and dexamethasone is one of the best options for multiple myeloma patients who have relapsed while on lenalidomide, but other data are in the offing that could provide even more options, said Professor Philippe Moreau, head of the haematology department at University Hospital in Nantes, France.

IMW 2019: As treatment options explode, questions remain myriad in myeloma

Article written by Tom Collins. Interview by Esther Drain. Meletios Dimopoulos, MD, professor and chairman of clinical therapeutics at the University of Athens and a long-time expert in… read more.

IMW 2019: Panel debate merits of transplantation

Article written by Tom Collins. Interview by Esther Drain In a debate about whether autologous stem cell transplant (ASCT) is still right for all transplant eligible MM patients,… read more.

Translational oncology symposium

The use of tyrosine kinase inhibitors (TKIs) in the treatment of ALK-positive NSCLC is now well-established. Professor Ross Camidge (University of Colorado Cancer Centre, Denver, USA) described the lessons that… read more.

Zejula sNDA submitted to FDA for ovarian, fallopian tube, or primary peritoneal cancer – Tesaro

Tesaro has submitted a supplemental New Drug Application (sNDA) to the FDA for Zejula (niraparib). The application was granted priority review and has an action date of 24 October 2019.

Mesothelioma trials update

Dr Popat gives an update of the ongoing studies in mesothelioma in the UK